BRISTOL-MYERS SQUIBB COMPANY (NYSE: BMY)

BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

最近更新时间: 05 Jul, 8:37AM

46.92

-0.09 (-0.19%)

加入群组

前收盘价格	47.01
收盘价格	47.21
成交量	7,024,133
平均成交量 (3个月)	15,512,116
市值	95,485,943,808

市盈率 (P/E TTM)	17.51
预期市盈率 (P/E Forward)	7.75
价格/销量 (P/S)	2.07
股市价格/股市净资产 (P/B)	5.67

52周波幅	39.50 (-15%) — 63.33 (34%)
利润日期	31 Jul 2025
股息率 (DY TTM)	3.88%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看跌	混合的
	Drug Manufacturers - General (全球的)	看跌	混合的
股票	Bristol-Myers Squibb Company	看跌	看跌

AIStockmoo 评分

0.3

分析师共识	-3.5
内部交易活动	NA
价格波动	1.5
技术平均移动指标	1.0
技术振荡指标	2.0
平均	0.25

相关股票

股票	市值	DY	P/E（TTM）	P/B
BMY	95 B	3.88%	17.51	5.67
JNJ	401 B	2.24%	17.83	5.21
ABBV	335 B	3.36%	81.10	229.94
PFE	135 B	5.36%	17.18	1.50
GSK	78 B	2.03%	18.27	3.99
LLY	723 B	0.51%	65.48	43.95

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Value
内部持股比例	0.07%
机构持股比例	82.11%

52周波幅	39.50 (-15%) — 63.33 (34%)
中	34.00 (-27.54%)
总计	1 卖出

公司	日期	目标价格	调整类型	价格@调整类型
Morgan Stanley	10 Jul 2025	34.00 (-27.54%)	卖出	48.52

该时间范围内无数据。

日期	类型	细节
31 Jul 2025	公告	Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
31 Jul 2025	CNBC	Pandemic darlings Moderna, BioNTech are now on two different paths
28 Jul 2025	公告	Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
25 Jul 2025	公告	Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
21 Jul 2025	公告	Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
18 Jul 2025	公告	Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
17 Jul 2025	公告	Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
17 Jul 2025	CNBC	Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
26 Jun 2025	公告	U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
17 Jun 2025	公告	Bristol Myers Squibb Announces Dividend
17 Jun 2025	CNBC	Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
16 Jun 2025	公告	Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
12 Jun 2025	公告	Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
12 Jun 2025	公告	Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
11 Jun 2025	公告	Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
10 Jun 2025	公告	Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus roya...
02 Jun 2025	公告	BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
28 May 2025	公告	Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
28 May 2025	公告	Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
22 May 2025	公告	Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
21 May 2025	公告	Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
16 May 2025	公告	Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
12 May 2025	CNBC	Trump's plan to slash drug prices may struggle to get off the ground – here's what to know
06 May 2025	公告	Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
显示更多

股息率 (DY TTM)	3.88%
5年平均股息收益率	3.55%
股息支付比率	91.04%
预计下次股息支付	Nov 2025

除息日	公告日期	支付日期	详情
03 Jan 2025	11 Dec 2024	03 Feb 2025	0.62 现金
04 Oct 2024	10 Sep 2024	01 Nov 2024	0.6 现金
05 Jul 2024	18 Jun 2024	01 Aug 2024	0.6 现金
04 Apr 2024	01 Mar 2024	01 May 2024	0.6 现金
04 Jan 2024	06 Dec 2023	01 Feb 2024	0.6 现金
05 Oct 2023	20 Sep 2023	01 Nov 2023	0.57 现金
06 Jul 2023	14 Jun 2023	01 Aug 2023	0.57 现金
06 Apr 2023	03 Mar 2023	01 May 2023	0.57 现金
05 Jan 2023	08 Dec 2022	01 Feb 2023	0.57 现金
06 Oct 2022	14 Sep 2022	01 Nov 2022	0.54 现金
30 Jun 2022	15 Jun 2022	01 Aug 2022	0.54 现金
31 Mar 2022	01 Mar 2022	02 May 2022	0.54 现金
06 Jan 2022	13 Dec 2021	01 Feb 2022	0.54 现金
30 Sep 2021	09 Sep 2021	01 Nov 2021	0.49 现金
01 Jul 2021	17 Jun 2021	02 Aug 2021	0.49 现金
31 Mar 2021	01 Mar 2021	03 May 2021	0.49 现金
31 Dec 2020	10 Dec 2020	01 Feb 2021	0.49 现金
01 Oct 2020	10 Sep 2020	02 Nov 2020	0.45 现金
02 Jul 2020	11 Jun 2020	03 Aug 2020	0.45 现金
02 Apr 2020	02 Mar 2020	01 May 2020	0.45 现金
02 Jan 2020	06 Dec 2019	03 Feb 2020	0.45 现金
03 Oct 2019	12 Sep 2019	01 Nov 2019	0.41 现金
03 Jul 2019	14 Jun 2019	01 Aug 2019	0.41 现金
04 Apr 2019	08 Mar 2019	01 May 2019	0.41 现金
03 Jan 2019	07 Dec 2018	01 Feb 2019	0.41 现金
04 Oct 2018	13 Sep 2018	01 Nov 2018	0.4 现金
05 Jul 2018	15 Jun 2018	01 Aug 2018	0.4 现金
05 Apr 2018	01 Mar 2018	01 May 2018	0.4 现金
04 Jan 2018	07 Dec 2017	01 Feb 2018	0.4 现金
05 Oct 2017	13 Sep 2017	01 Nov 2017	0.39 现金
05 Jul 2017	13 Jun 2017	01 Aug 2017	0.39 现金
05 Apr 2017	02 Mar 2017	01 May 2017	0.39 现金
04 Jan 2017	08 Dec 2016	01 Feb 2017	0.39 现金
05 Oct 2016	03 Aug 2016	01 Nov 2016	0.38 现金
29 Jun 2016	07 Jun 2016	01 Aug 2016	0.38 现金
30 Mar 2016	03 Mar 2016	02 May 2016	0.38 现金
30 Dec 2015	08 Dec 2015	01 Feb 2016	0.38 现金
30 Sep 2015	17 Sep 2015	02 Nov 2015	0.37 现金
01 Jul 2015	16 Jun 2015	03 Aug 2015	0.37 现金
01 Apr 2015	02 Mar 2015	01 May 2015	0.37 现金
30 Dec 2014	09 Dec 2014	02 Feb 2015	0.37 现金
01 Oct 2014	16 Sep 2014	03 Nov 2014	0.36 现金
01 Jul 2014	17 Jun 2014	01 Aug 2014	0.36 现金
02 Apr 2014	03 Mar 2014	01 May 2014	0.36 现金
31 Dec 2013	19 Dec 2013	03 Feb 2014	0.36 现金
02 Oct 2013	17 Sep 2013	01 Nov 2013	0.35 现金
02 Jul 2013	19 Jun 2013	01 Aug 2013	0.35 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	0.620	1	1.32
2024	2.40	4	4.24
2023	2.28	4	4.44
2022	2.16	4	3.00
2021	1.96	4	3.14
2020	1.80	4	2.90
2019	1.64	4	2.56
2018	1.60	4	3.08
2017	1.56	4	2.55
2016	1.52	4	2.60
2015	1.48	4	2.15
2014	1.44	4	2.44
2013	0.700	2	1.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	11.38%
营业利益率 (TTM)	31.57%
稀释每股收益 (EPS TTM)	2.68
季度收入增长率 (YOY)	-5.60%
季度盈利增长率 (YOY)	-95.90%

总债务/股东权益 (D/E MRQ)	293.85%
流动比率 (MRQ)	1.28
营业现金流 (OCF TTM)	14.31 B
杠杆自由现金流 (LFCF TTM)	13.93 B

资产报酬率 (ROA TTM)	7.24%
股东权益报酬率 (ROE TTM)	31.99%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)